Betel Nut Use Disorder

Overview

Betel nut (also called areca nut) is the seed of the Areca catechu palm, traditionally chewed for its stimulant effects in many parts of South‑Asia, Southeast‑Asia, the Pacific Islands and among immigrant communities worldwide. When a person develops a pattern of persistent, compulsive use that leads to clinically significant distress or impairment, the condition is classified as **Betel Nut Use Disorder (BNUD)**—a behavioral addiction recognized under the broader category of “substance‑related and addictive disorders.”

Who it affects

• Predominantly men (≈70 % of users), though women’s use is rising especially in India, Taiwan, and Papua New Guinea.
• Typical onset: late adolescence to early‑mid‑30s, coinciding with cultural initiation rituals.
• Higher prevalence among lower socioeconomic groups and in rural areas where betel cultivation is common.

Prevalence

• World Health Organization (WHO) estimates > 600 million current betel nut chewers globally (≈10 % of the world’s population) ¹.
• In India, national surveys report 22 % of adults chew betel nut daily; among those, ~15 % meet criteria for a use disorder ².
• In Taiwan, the prevalence of betel‑quid dependence among men aged 20–64 is 10.8 % (higher than nicotine dependence) ³.

Symptoms

Betel nut use disorder manifests with a combination of physical, psychological, and behavioral signs. The following list reflects the diagnostic criteria adapted from the DSM‑5 for “other (or unknown) substance‑related disorder.”

Physical symptoms

• Oral changes: Red‑brown staining of the teeth and mucosa, “betel‑stain” keratotic plaques, increased salivation.
• Gastro‑intestinal: Nausea, vomiting, dyspepsia, loss of appetite.
• Cardiovascular: Tachycardia, mild hypertension due to the stimulant alkaloid arecoline.
• Neurological: Restlessness, insomnia, headache, tremor.
• Withdrawal signs (when use is reduced): Irritability, anxiety, cravings, sweating, fatigue.

Psychological symptoms

• Intense craving for betel nut that occupies much of the thinker’s time.
• Loss of control – larger amounts or longer periods than intended.
• Persistent desire or unsuccessful attempts to cut down.
• Continued use despite knowledge of physical harm.

Behavioral / Social symptoms

• Spending a great deal of time obtaining, preparing, or using betel quid.
• Neglect of work, school, or family responsibilities.
• Social isolation or conflict related to chewing habit.
• Financial strain from purchasing large quantities.

Causes and Risk Factors

Betel nut use disorder is multifactorial, involving biological, psychosocial, and cultural components.

Biological factors

• Pharmacology of arecoline: A muscarinic agonist that produces mild euphoria, alertness, and appetite suppression.
• Genetic susceptibility: Polymorphisms in dopamine‑related genes (e.g., DRD2, COMT) have been linked to higher odds of dependence ⁴.

Psychosocial factors

• Early exposure through family members or peers (peer pressure, “ritual” chewing).
• Stressful life events, low self‑esteem, or co‑occurring mental health disorders (depression, anxiety).
• Availability and low cost of betel quid compared with cigarettes or alcohol.

Cultural factors

• Betel nut is embedded in many traditions (weddings, religious ceremonies, hospitality).
• Misconception that it is “harmless” or even “medicinal.”

Risk groups

• Adolescents in regions where betel quid is socially accepted.
• Individuals with a family history of substance use disorders.
• People with limited access to education/health information.

Diagnosis

Diagnosis is clinical, based on a detailed history and examination, supplemented by laboratory and imaging studies when indicated.

Step‑by‑step approach

1. History taking: Frequency, amount, method of preparation (with tobacco, slaked lime, spices), age of initiation, attempts to quit, and impact on daily life.
2. Screening tools: Adapted versions of the Alcohol Use Disorders Identification Test (AUDIT‑C) or the Betel Quid Dependence Scale (BQDS) can quantify severity ⁵.
3. Physical examination: Look for oral lesions, dental attrition, hepatomegaly (in heavy users) and signs of systemic toxicity.
4. Laboratory tests:
   • Complete blood count (CBC) – may reveal anemia or leukocytosis.
   • Liver function tests – elevated ALT/AST in chronic heavy users.
   • Urine or saliva cotinine if other substances are co‑used.
5. Imaging (if indicated): Panoramic dental X‑ray for precancerous lesions; ultrasound/CT for hepatobiliary complications.
6. Diagnostic criteria: At least two of the DSM‑5‑style symptoms listed above must be present within a 12‑month period, causing distress or functional impairment.

Treatment Options

Effective management combines behavioral therapy, pharmacology (when needed), and community‑based support.

Psychosocial interventions

• Cognitive‑behavioral therapy (CBT): Helps identify triggers, develop coping strategies, and restructure maladaptive thoughts.
• Motivational interviewing (MI): Enhances readiness to change, especially useful for individuals ambivalent about quitting.
• Contingency‑management programs: Provide monetary or voucher incentives for verified abstinence.
• Peer‑support groups: Community‑based “Quit‑Betel” circles modeled after Tobacco‑Free groups.

Pharmacologic options

There is no FDA‑approved medication specifically for BNUD, but several agents have shown promise in pilot studies.

• Bupropion (150–300 mg/day): Reduces cravings and withdrawal; used off‑label similar to nicotine dependence.
• Naltrexone (50 mg/day): May attenuate the rewarding effects of arecoline.
• Topical nicotine replacement (gum, patch): Occasionally used when betel quid contains tobacco, to address dual nicotine dependence.
• All medications require monitoring for side‑effects and should be prescribed by clinicians experienced in addiction medicine.

Medical management of complications

• Dental care for oral leukoplakia or periodontal disease.
• Antifibrotic therapy for liver fibrosis (e.g., ursodeoxycholic acid) after specialist evaluation.

Lifestyle & environmental changes

• Gradual reduction (“tapering”) of chew size and frequency.
• Substituting with harmless oral fixations—chewing sugar‑free gum, crunchy vegetables.
• Avoiding situations that cue use (social gatherings where quid is offered).

Living with Betel Nut Use Disorder

Long‑term success stems from daily habits that reinforce abstinence and protect oral health.

Practical tips

1. Create a quit plan: Set a quit date, list personal reasons, and anticipate high‑risk moments.
2. Track cravings: Use a journal or mobile app to note intensity, triggers, and coping responses.
3. Maintain oral hygiene: Brush twice daily with fluoride toothpaste, floss, and schedule regular dental check‑ups.
4. Stay hydrated and eat balanced meals: Proper nutrition reduces the “empty‑mouth” sensation that often prompts chewing.
5. Engage in physical activity: Exercise releases endorphins that counteract cravings.
6. Seek social support: Tell family and friends about your goals; ask them to refrain from offering betel quid.
7. Manage stress: Practice mindfulness, deep‑breathing, or yoga to reduce reliance on the stimulant effect.
8. Monitor health: Keep a log of any new oral lesions, weight loss, or gastrointestinal symptoms and report them promptly.

Prevention

Because cultural acceptance drives initiation, prevention requires community‑level and individual actions.

• Education campaigns: School‑based programs that highlight the carcinogenic risk (arecoline classified as a Group 1 carcinogen by IARC) ⁶.
• Regulation: Implement taxation, age restrictions, and labeling requirements for commercial betel quid products.
• Alternative rituals: Encourage cultural shifts toward non‑chewing symbols of hospitality (e.g., fruit or sweetmeats).
• Screening: Routine oral examinations for adolescents in high‑prevalence regions to catch early use.
• Family involvement: Parents who model non‑use and discuss health risks reduce the likelihood of adolescent uptake.